Skip to main content
NewslettersWatchlist

Numinus Wellness Inc(NUMI-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.0750
Day High0.0800
Open:0.0750
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Numinus Wellness Inc up on Friday (NUMI)
Baystreet
Stocks in play: Numinus Wellness Inc.
Newswire.ca
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
AI-generated - The Globe and Mail
Numinus Wellness: Top 10 Undervalued Growth Stocks on TSX (NUMI)
Baystreet
Stocks in play: Numinus Wellness Inc.
Newswire.ca
Cedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003
Newswire.ca
Numinus Wellness Provides Corporate Update
Newswire.ca
Numinus Wellness Inc. Announces Second Quarter Fiscal 2024 Results
Newswire.ca
Numinus to Host Q2 Fiscal 2024 Results Conference Call on April 15, 2024
Newswire.ca
Numinus Wellness Submits Clinical Trial Application
Newswire.ca
Numinus Wellness Provides Corporate Update
Newswire.ca
Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder
AI-generated - The Globe and Mail
Numinus Wellness: Top 10 Undervalued Healthcare Sector Stocks on TSX (NUMI)
AI-generated - The Globe and Mail
Numinus Wellness: Top 10 Undervalued Healthcare Providers & Services Industry Stocks (NUMI)
BayStreet.ca
This May be One of the Biggest Catalysts for Psychedelic Stocks in 2024
Baystreet
Stocks in play: Numinus Wellness Inc.
Newswire.ca
Numinus Wellness Inc. Closes $6 Million Bought Deal Public Offering
Baystreet
Stocks in play: Numinus Wellness Inc.
BayStreet.ca
Breaking: The US FDA Just Granted Priority Review of an MDMA Treatment for PTSD
Newswire.ca
Numinus Wellness Inc. Congratulates Lykos Therapeutics on FDA Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD
AI-generated - The Globe and Mail
Numinus Wellness: Top 10 Undervalued Nano Cap Stocks on TSX (NUMI)
AI-generated - The Globe and Mail
Numinus Wellness: Top 10 Undervalued Healthcare Sector Stocks on TSX (NUMI)
AI-generated - The Globe and Mail
Numinus Wellness: Top 10 Undervalued Healthcare Providers & Services Industry Stocks (NUMI)
AI-generated - The Globe and Mail
Numinus Wellness: Top 25 Undervalued Toronto Stock Exchange Stocks (NUMI)
GlobeNewswire
Numinus Wellness Inc. Announces $6 Million Bought Deal Public Offering with Leads Orders from MAPS and Integrated V.C.
Newswire.ca
Numinus Wellness Divests of Holdings in Alto Neuroscience Inc.
Newswire.ca
Numinus Wellness Divests of Holdings in Co-Investment Feeder Fund 3.
AI-generated - The Globe and Mail
Numinus Wellness: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (NUMI)
Newswire.ca
Numinus Wellness Inc. Announces First Quarter Fiscal 2024 Results
Baystreet
Americans Enjoy Shortened Week
Newswire.ca
Numinus to Host Q1 Fiscal 2024 Results Conference Call on January 15, 2024
Newswire.ca
Cedar Clinical Research selected as clinical research site for Beckley Psytech's Phase 2b Study

Profile

Numinus Wellness Inc develops proprietary, psychedelic-centered, therapeutic products and services through its laboratory and research & development processes. The company's clinic network consists of Numinus Health, Mindspace Services, and the Neurology Center of Toronto. Its services include Ketamine-assisted psychotherapy for depression, neurological care, psychotherapy, and counseling by registered psychologists among others. The company's operating segments are; Clinical research operations, Canadian clinic network, US clinic network and Corporate. The majority of the revenue for the company is generated from US clinic network segment. Geographically, the company has its presence in United States and Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.